BeBetter Med
BeBetter Med is a Guangzhou biotechnology company developing BEBT-908, a dual PI3K and HDAC inhibitor for relapsed lymphoma, and other small-molecule cancer drugs, with three late-stage trials in the registry.
Overview
BeBetter Med, based in Guangzhou, develops small-molecule cancer drugs. Its lead programme BEBT-908 inhibits both PI3K and histone deacetylases and has been studied in relapsed or refractory diffuse large B-cell lymphoma and other lymphomas, and the company runs further trials of its pipeline in solid tumours. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.
Similar pages
not linked directly; found by shared links- CompanyRanok Therapeutics (Hangzhou)
Shares Diffuse large B-cell lymphoma and the tag ctgov-sponsor.
- CompanyMiltenyi Biomedicine
Shares Diffuse large B-cell lymphoma and the tag ctgov-sponsor.
- CompanyKartos Therapeutics
Shares Diffuse large B-cell lymphoma and the tag ctgov-sponsor.
- TreatmentBEBT-209
Shares A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer, Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy.
- CompanySinocelltech
Shares Diffuse large B-cell lymphoma and the tag ctgov-sponsor.
- TreatmentIfupinostat
Shares Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Diffuse large B-cell lymphoma.